Bayer

This sponsor has funded 75 studies across 55 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
1597 Finalised Yes Yes
1613 Finalised Yes Yes
2679 Finalised Yes No
3911 Finalised Yes Yes
3979 Finalised Yes Yes
4564 Finalised Yes Yes
4934 Finalised Yes Yes
5944 Finalised Yes Yes
6115 Finalised Yes Yes
6476 Ongoing Yes No
7187 Ongoing Yes No
8365 Finalised Yes Yes
8412 Finalised Yes Yes
8494 Finalised Yes Yes
8498 Finalised Yes Yes
9020 Finalised Yes Yes
9312 Finalised Yes Yes
9895 Finalised Yes Yes
9977 Finalised Yes Yes
9991 Finalised Yes Yes
10249 Finalised Yes Yes
10837 Finalised Yes Yes
11141 Finalised Yes Yes
11145 Finalised Yes Yes
11299 Finalised Yes Yes
12608 Finalised Yes Yes
12665 Finalised Yes Yes
13054 Finalised Yes Yes
13602 Finalised Yes Yes
14567 Finalised Yes Yes
15459 Finalised Yes Yes
15491 Finalised Yes Yes
15687 Finalised Yes Yes
15755 Finalised Yes Yes
15961 Finalised Yes Yes
18521 Finalised Yes Yes
20981 Finalised Yes Yes
21253 Finalised Yes Yes
21800 Finalised Yes Yes
23099 Finalised Yes Yes
23347 Finalised Yes Yes
23407 Finalised Yes Yes
24270 Finalised Yes Yes
24796 Finalised Yes Yes
25089 Finalised Yes Yes
26416 Ongoing Yes No
26922 Finalised Yes No
28126 Finalised No Yes
28234 Finalised Yes Yes
29848 Finalised Yes Yes
30727 Finalised Yes Yes
31146 Ongoing No No
31734 Ongoing No No
32136 Ongoing Yes No
32349 Finalised Yes Yes
33167 Ongoing Yes No
33448 Finalised Yes Yes
33461 Finalised Yes Yes
33520 Ongoing Yes No
33537 Finalised Yes Yes
33562 Finalised Yes Yes
36102 Finalised Yes Yes
36634 Finalised Yes Yes
37163 Finalised Yes Yes
37597 Finalised Yes Yes
38736 Planned Yes No
39592 Ongoing No No
41194 Finalised Yes Yes
43329 Finalised Yes Yes
43355 Finalised Yes Yes
46493 Ongoing Yes No
46800 Planned Yes No
47805 Finalised Yes Yes
48148 Ongoing Yes No
105067 Ongoing No No

PAS by Risk Management Plan (RMP) requirement

Bayer

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.